vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Porch Group, Inc. (PRCH). Click either name above to swap in a different company.
Porch Group, Inc. is the larger business by last-quarter revenue ($121.1M vs $86.8M, roughly 1.4× IOVANCE BIOTHERAPEUTICS, INC.). On growth, Porch Group, Inc. posted the faster year-over-year revenue change (100.0% vs 17.7%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 26.4%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Porch is a website that tries to connect homeowners with local home improvement contractors. The site features advice articles, cost guide, and online booking for over 160 home projects.
IOVA vs PRCH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $121.1M |
| Net Profit | — | $-4.7M |
| Gross Margin | 67.4% | 52.7% |
| Operating Margin | -84.7% | 34.7% |
| Net Margin | — | -3.9% |
| Revenue YoY | 17.7% | 100.0% |
| Net Profit YoY | — | 2.0% |
| EPS (diluted) | — | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $121.1M | ||
| Q4 25 | $86.8M | $112.3M | ||
| Q3 25 | $67.5M | $115.1M | ||
| Q2 25 | $60.0M | $107.0M | ||
| Q1 25 | $49.3M | $84.5M | ||
| Q4 24 | $73.7M | $75.3M | ||
| Q3 24 | $58.6M | $77.7M | ||
| Q2 24 | $31.1M | $75.9M |
| Q1 26 | — | $-4.7M | ||
| Q4 25 | — | $-3.5M | ||
| Q3 25 | $-91.3M | $-10.9M | ||
| Q2 25 | $-111.7M | $2.6M | ||
| Q1 25 | $-116.2M | $8.4M | ||
| Q4 24 | — | $30.5M | ||
| Q3 24 | $-83.5M | $14.4M | ||
| Q2 24 | $-97.1M | $-64.3M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | 67.4% | 99.5% | ||
| Q3 25 | 43.0% | 75.6% | ||
| Q2 25 | 5.5% | 70.9% | ||
| Q1 25 | -0.8% | 77.4% | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | 79.4% | ||
| Q2 24 | -0.8% | 22.1% |
| Q1 26 | — | 34.7% | ||
| Q4 25 | -84.7% | 14.7% | ||
| Q3 25 | -140.7% | 14.2% | ||
| Q2 25 | -189.8% | 4.7% | ||
| Q1 25 | -245.8% | -1.5% | ||
| Q4 24 | -117.5% | 33.3% | ||
| Q3 24 | -152.1% | -3.2% | ||
| Q2 24 | -327.6% | -69.2% |
| Q1 26 | — | -3.9% | ||
| Q4 25 | — | -3.1% | ||
| Q3 25 | -135.3% | -9.4% | ||
| Q2 25 | -186.2% | 2.4% | ||
| Q1 25 | -235.5% | 9.9% | ||
| Q4 24 | — | 40.5% | ||
| Q3 24 | -142.7% | 18.5% | ||
| Q2 24 | -312.2% | -84.8% |
| Q1 26 | — | $-0.04 | ||
| Q4 25 | — | $0.00 | ||
| Q3 25 | — | $-0.10 | ||
| Q2 25 | $-0.33 | $0.00 | ||
| Q1 25 | $-0.36 | $0.07 | ||
| Q4 24 | $-0.24 | $0.34 | ||
| Q3 24 | $-0.28 | $0.12 | ||
| Q2 24 | $-0.34 | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $68.4M |
| Total DebtLower is stronger | — | $391.3M |
| Stockholders' EquityBook value | $698.6M | $26.3M |
| Total Assets | $913.2M | $806.6M |
| Debt / EquityLower = less leverage | — | 14.87× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $68.4M | ||
| Q4 25 | $297.0M | $57.3M | ||
| Q3 25 | $300.8M | $85.0M | ||
| Q2 25 | $301.2M | $79.8M | ||
| Q1 25 | $359.7M | $70.4M | ||
| Q4 24 | $323.8M | $191.7M | ||
| Q3 24 | $397.5M | $238.6M | ||
| Q2 24 | $412.5M | $308.4M |
| Q1 26 | — | $391.3M | ||
| Q4 25 | — | $392.8M | ||
| Q3 25 | — | $387.1M | ||
| Q2 25 | — | $394.1M | ||
| Q1 25 | — | $409.2M | ||
| Q4 24 | — | $403.9M | ||
| Q3 24 | — | $399.0M | ||
| Q2 24 | — | $436.8M |
| Q1 26 | — | $26.3M | ||
| Q4 25 | $698.6M | $-24.6M | ||
| Q3 25 | $702.3M | $-27.9M | ||
| Q2 25 | $698.5M | $-29.3M | ||
| Q1 25 | $767.9M | $-52.4M | ||
| Q4 24 | $710.4M | $-43.2M | ||
| Q3 24 | $773.5M | $-77.0M | ||
| Q2 24 | $768.5M | $-101.9M |
| Q1 26 | — | $806.6M | ||
| Q4 25 | $913.2M | $797.4M | ||
| Q3 25 | $904.9M | $787.7M | ||
| Q2 25 | $907.4M | $770.7M | ||
| Q1 25 | $966.7M | $802.3M | ||
| Q4 24 | $910.4M | $814.0M | ||
| Q3 24 | $991.1M | $867.3M | ||
| Q2 24 | $964.3M | $876.1M |
| Q1 26 | — | 14.87× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | — |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-52.6M | $1.2M | ||
| Q3 25 | $-78.7M | $40.8M | ||
| Q2 25 | $-67.4M | $35.6M | ||
| Q1 25 | $-103.7M | $-11.2M | ||
| Q4 24 | $-73.3M | $-26.6M | ||
| Q3 24 | $-59.0M | $12.4M | ||
| Q2 24 | $-98.4M | $-26.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-61.9M | $1.1M | ||
| Q3 25 | $-89.5M | $40.7M | ||
| Q2 25 | $-74.9M | $35.4M | ||
| Q1 25 | $-109.9M | $-11.2M | ||
| Q4 24 | $-77.5M | $-26.8M | ||
| Q3 24 | $-61.3M | $12.2M | ||
| Q2 24 | $-98.9M | $-26.0M |
| Q1 26 | — | — | ||
| Q4 25 | -71.3% | 1.0% | ||
| Q3 25 | -132.7% | 35.4% | ||
| Q2 25 | -124.9% | 33.0% | ||
| Q1 25 | -222.8% | -13.3% | ||
| Q4 24 | -105.1% | -35.6% | ||
| Q3 24 | -104.6% | 15.7% | ||
| Q2 24 | -317.9% | -34.3% |
| Q1 26 | — | — | ||
| Q4 25 | 10.7% | 0.1% | ||
| Q3 25 | 16.1% | 0.1% | ||
| Q2 25 | 12.4% | 0.2% | ||
| Q1 25 | 12.6% | 0.1% | ||
| Q4 24 | 5.7% | 0.3% | ||
| Q3 24 | 3.9% | 0.3% | ||
| Q2 24 | 1.4% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 13.79× | ||
| Q1 25 | — | -1.33× | ||
| Q4 24 | — | -0.87× | ||
| Q3 24 | — | 0.86× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
PRCH
Segment breakdown not available.
